Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Will Edwards' (EW) Growth in All Lines Drive Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.
Varian Medical (VAR) Launches Velocity 4.0, Shares Rise
by Zacks Equity Research
The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.
Here's Why You Should Hold on to Varian Medical Stock Now
by Zacks Equity Research
Here we take a peek at Varian Medical's (VAR) performance to analyze why investors should hold on to this stock despite adversities.
Align Unveils Vivera Retainers for Deep Bite Correction
by Zacks Equity Research
Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.
Walgreens Boots' Retail Business Solid Amid Several Concerns
by Zacks Equity Research
Walgreens Boots (WBA) progresses with consistent sales rise in the Retail Pharmacy International business. Moreover, the stock grows on strategic alliances.
Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
by Zacks Equity Research
Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.
Walgreens Boots (WBA) Beats on Earnings in Q2, Lifts View
by Zacks Equity Research
Walgreens Boots (WBA) witnesses revenue growth across all three segments in Q2. A solid guidance instills investor confidence in the stock.
DexCom (DXCM) Gets FDA Approval for G6 CGM Monitoring System
by Zacks Equity Research
DexCom (DXCM) is a leading player in the global CGM markets.
Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Walgreens Boots' (WBA) increase in sales at the Retail Pharmacy International segment, on account of the company's strategic tie-ups, along with strength in other businesses buoy optimism.
3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax
by Zacks Equity Research
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
Can Edwards Lifesciences (EW) Stock Continue to Grow Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
Medical Device Industry Outlook - February 2018
by Zacks Equity Research
Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Recent buyouts and CE Mark boost investors' confidence in Edwards Lifesciences (EW).
Edwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm
by Zacks Equity Research
Edward Lifesciences (EW) witnesses multiple developments in THV segment.
Markets Are Down, But These Stocks Surged to All-Time Highs Today
by Ryan McQueeney
Friday has been a rough day on Wall Street, with several major indexes--including the Dow, Nasdaq, and S&P 500--hovering deep in the red during early afternoon trading hours. Nevertheless, several notable stocks touched new all-time highs during the day. Check them out!
Is a Surprise Coming for Edwards Lifesciences (EW) This Earnings Season?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.
Edwards Lifesciences Buys Harpoon Medical, Expands Portfolio
by Zacks Equity Research
Edwards Lifesciences (EW) expands Surgical Heart Valve Therapy segment with the buyout of Harpoon Medical.
Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options
by Zacks Equity Research
Edwards Lifesciences (EW) needs investors to pay close attention to the stock based on moves in the options market lately.
EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?
by Zacks Equity Research
Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.
Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.
Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day
Align Technology (ALGN) Prospects Bright, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
The #1 non-surgical heart valve replacement technology owes its roots to a hydraulic pump engineer named Miles Edwards